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Abstract
Background: Many putative disease blood biomarkers discovered in genomic and proteomic
studies await validation in large clinically annotated cohorts of patient samples. ELISA assays require
large quantities of precious blood samples and are not high-throughput. The reverse phase protein
microarray platform has been developed for the high-throughput quantification of protein levels in
small amounts of clinical samples.
Results: In the present study we present the development of reverse-phase protein microarrays
(RPPMs) for the measurement of clusterin, a mid-abundant blood biomarker. An experimental
protocol was optimized for the printing of serum and plasma on RPPMs using epoxy coated
microscope slides and a non-denaturing printing buffer. Using fluorescent-tagged secondary
antibodies, we achieved the reproducible detection of clusterin in spotted serum and plasma and
reached a limit of detection of 780 ng/mL. Validation studies using both spiked clusterin and clinical
samples showed excellent correlations with ELISA measurements of clusterin.
Conclusion: Serum and plasma spotted in the reverse phase array format allow for reliable and
reproducible high-throughput validation of a mid-abundant blood biomarker such as clusterin.
Background
The increasing application of genomics and proteomics
technologies in medical research is making possible the
development of "personalized medicine", i.e. medical
care characterized by the use of biomarkers for the molec-
ular diagnosis of different disease states and for the selec-
tion of therapies tailored to the individual's disease.
Although both tissue and blood biomarkers are being dis-
covered, blood derived-biomarkers are particularly attrac-
tive in the clinic since blood collection is inexpensive and
relatively non-invasive and blood comes in contact with
all tissues in the body. Unfortunately, the translation of
putative blood biomarkers into clinical application has
been hindered by the lack of a high-throughput technical
platform for their validation. ELISAs are the standard
method currently used for blood biomarker validation.
However, the requirement for large sample volumes
(~100 μl) and its low throughput make ELISA a costly
method, both in time and biological material, not suited
for the rapid validation of clinical samples.
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A novel technology designed to measure protein levels in
a high-throughput fashion is the protein microarray [1,2].
There are two main types of protein microarrays. The for-
ward phase format consists of bait molecules, usually
antibodies that are immobilized on the slide surface.
Slides containing hundreds or thousands of antibodies
are then incubated with the sample of interest (e.g., cell
lysate or serum) allowing the simultaneous screening of a
large number of putative protein biomarkers in a single
test sample [1]. In the reverse phase array format, minute
amounts of biological samples are printed onto the array
surface. Cell and tissue lysates as well as biological fluids
such as urine, CSF, serum and plasma can be spotted onto
such arrays. Slides containing these sample sets are then
incubated with antibodies targeted against a single pro-
tein of interest, one marker per slide. Analytes can be
detected using amplification methods or with tagged sec-
ondary antibodies. Thus, reverse phase protein microar-
rays enable the high-throughput screening of thousands
of clinical samples in a single microarray experiment [3].
Reverse phase protein microarrays (RPPMs) have been
successfully applied for the profiling of post-translational
modifications and cell signalling pathways in cell and tis-
sue lysates [4-6] and the protocols for this application
have been well described [7]. In contrast, only a few stud-
ies report the use of this type of array for serum and
plasma applications with results limited to the detection
of highly abundant proteins [8,9] using different proto-
cols.
In the present study we describe the development of a pro-
tocol to print serum and plasma on RPPMs for the meas-
urement of clusterin. Clusterin is a mid abundant blood
protein present in serum and plasma in the μg/mL range
[10]. Also known as apolipoprotein J, this apoptosis-
related protein exists in two major isoforms. The nuclear
form (nCLU), generated from an alternative splicing
event, is a 55 kDa protein with pro-apoptotic properties
[11]. The secreted form (sCLU) is a 75–80 kDa heavily gly-
cosylated heterodimer composed of α and β chains of
approx 34–37 kDa and has pro-survival functions [12].
Many recent studies have reported important roles of clus-
terin in carcinogenesis [13], tumorigenesis [14] and
chemoresistance [15] and its expression level has been
shown to be deregulated in several cancers, suggesting a
potential clinical use as a cancer biomarker [13]. We have
performed comparative analyses of clusterin detection
using different slide chemistries and buffers for printing
serum and plasma samples in the reverse phase format.
We report the limit of detection, dynamic range, intra and
inter array reproducibility as well as the results from vali-
dation studies using ELISAs with our optimized protocol.
Methods
Antibodies
The primary antibodies used were polyclonal anti-clus-
terin-α (C-18): sc-6419 (Santa Cruz, CA) and monoclonal
anti-clusterin-α (B-5): sc-5289 (Santa Cruz, CA). Detec-
tion antibodies were Cy3 anti-mouse IgG and Cy3 anti-
goat IgG (Jackson Immuno Research, U.S.A.). All primary
antibodies were used at a 1:20 dilution in buffer (PBS con-
taining 3% BSA) and all secondary antibodies were used
at 1:100 dilution in the same buffer.
Slides
Three types of slides were tested:
Nitrocellulose slides (Grace Bio-Labs, Bend, OR), Max-
iSorp™ (Nunc Nalgene International) and SuperChip™
Glass Microarray slides with epoxyde surface coating (Erie
Scientific company, Portsmouth, NH).
Test Samples for Protocol Development and Optimization
Human plasma was obtained from Sigma and two-fold
serial dilutions were prepared by adding 2× commercially
available protein printing buffer (PPB) (ArrayIt®, Tel-
eChem International, Sunnyvale CA) or Urea buffer (3 M
Urea prepared in 1× PPB, 0.5% CHAPS, 32.5 mM DTT and
1% Pharmalyte 8-10-5). Control samples consisted of
PPB or Urea buffer alone.
For proof of concept experiments, serial dilutions of
mouse IgGs (Jackson Immuno Research, U.S.A.) and six
serial dilutions of plasma (Sigma) were prepared in PPB.
To assess the minimum difference detected and for ELISA
validation studies, recombinant clusterin (produced in-
house at the Biotechnology Research Institute) was pre-
pared in series of two-fold dilutions in PPB. Two volumes
of each dilution were added to corresponding tubes con-
taining one volume of plasma (Sigma) and one volume of
2× PPB to obtain final clusterin concentrations ranging
from 0.5 ng to 250 μg/mL and 0.9 to 500 μg/mL.
General Protocol for Array Preparation
Diluted samples were loaded onto 384 well plates (What-
man), and then arrayed onto the different slides using a
Virtek SDDC-2 arrayer (BioRad) and quill-type SMP3 con-
tact pins (TeleChem, Sunnyvale, CA). The array chamber
is equipped with a humidifier and humidity was set at
60% and temperature at 23°C during printing. Spot to
spot distance was set to 400 microns and the average spot
diameter obtained was 135–150 microns. After printing,
slides were allowed to dry in the arrayer overnight before
being directly used or kept in a dessicator until further
processing.
Printed slides were blocked for 2 hours with PBS, 3% BSA.
After blocking, slides were washed quickly in PBS, andProteome Science 2009, 7:15 http://www.proteomesci.com/content/7/1/15
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incubated with primary antibody solutions for 90 min at
room temperature. Slides were washed twice for 10 min in
PBST (PBS containing 0.1% Tween 20) followed by one 5
min wash in PBS and were then incubated in solutions
containing secondary antibodies conjugated to the fluo-
rescent dye for 2 hours at room temperature in the dark.
Slides were then washed again in PBST, as described
above, and then rinsed briefly in deionized water to
remove PBS buffer salts. The slides were air dried by spin-
ning at 800 rpm for 5 min and scanned with a ScanArray
Lite confocal fluorescent microarray scanner (Perkin
Elmer).
Data Analysis
Fluorescence was quantitated using the Histogram algo-
rithm in QuantArray® software (Packard Bioscience, Meri-
dan, CT). The raw fluorescence units of each spot were
background subtracted and the corrected fluorescence
value was used to calculate the average fluorescence signal
and standard deviation of replicate spots. For the analysis
of replicate arrays we performed a scaled normalization to
the median to minimize inter-array variability. Briefly, for
a series of arrays we defined a normalization constant Ci
by taking the median of the average fluorescent signals
(average of replicate spots) of each array. We also defined
a constant K by taking the median of the average fluores-
cent signals across all replicate arrays compared. We nor-
malized all the arrays to the common total median
intensity K by dividing all average fluorescent intensity
readings from array i by Ci and multiplying by K. The
median of all normalized values across arrays was calcu-
lated and considered the final fluorescent value of each
sample.
For the analysis of clinical samples, because of the large
number of data points, low intensity (raw fluorescence
units < 1000) and defective spots were first eliminated for
each array. Average, standard deviation and %CVs of rep-
licate spots were calculated and a cut-off of 20% for
acceptable reproducibility was set. For replicate spots with
%CV > 20% either one outlier spot was eliminated if pos-
sible to bring the %CV below 20%, or the whole sample
was eliminated from the analysis. Only reproducible data
was included in the correlation with ELISAs and calcula-
tion of scaling factor (see below).
To compare RPPM data and ELISA data, we calculated a
scaling factor by dividing the median intensity of each
array Ci by the median ELISA value of all samples meas-
ured. The fluorescence intensity obtained in each spot on
each array was then divided by the scaling factor to gener-
ate the scaled data.
Paired t-tests (GraphPad Prism Version 5) were performed
on clinical samples to compare the different collection
protocols. A value of p < 0.05 was considered as statisti-
cally significant.
Western Blot Analysis
Monoclonal and polyclonal antibodies against clusterin
were screened for specificity by Western Blot. The same
human plasma that was used for protocol development
was diluted 1/25, 1/50 and 1/100 in PBS and was incu-
bated with denaturing buffer and boiled for 3 minutes.
Denatured samples were loaded on a 10% SDS-PAGE and
recombinant clusterin was used as a positive control. After
gel migration (1 h at 150 V), proteins were transferred to
a PDVF membrane. The membrane was incubated with
1:1000 goat anti-human clusterin antibody (Santa Cruz)
as primary antibody and 1:10000 diluted HRP-conjugated
donkey anti-mouse IgG as secondary antibody. After
washing, the amount of bound HRP was visualized with
the ECL method (GE Healthcare, UK).
Clinical samples for Assay Validation
Blood was collected from eleven healthy non-fasting vol-
unteers who participated in a pilot study analysing the
effects of different blood collection protocols on plasma
biomarker levels. This study was approved by the Research
Ethics Office of the Jewish General Hospital. Informed
consent was obtained for all volunteers participating in
the study. Venipuncture was performed using a butterfly
needle (22 G; Sarstedt) and blood was drawn from a sit-
ting position. A total of five specimens per volunteer were
collected in the following order: 2 × 4.5 ml Vacutainer™
CTAD tubes (BD Biosciences), 1× 10 mL serum tube with
no additives (BD Biosciences) and 2 × 4.5 mL CTAD
tubes. CTAD tubes were inverted 10 times to allow for
adequate mixing of blood and buffer. For each pair of
CTAD tubes, blood was pooled and 1.5 mL aliquoted in
five 2 mL eppendorfs. One 1.5 mL aliquot was centrifuged
immediately (time 0) at 1300 × g for 10 minutes at room
temperature. The remaining four aliquots were left on the
bench to be centrifuged 30 min, 60 min, 120 min and 24
hrs after time 0, respectively. Following centrifugation,
approximately 500 μl of plasma was collected with a nee-
dle (16 G1 1/2; Sarstedt) and then filtered through an
Acrodisc® Syringe Filter unit (0.45 μm, 13 mm diameter)
(Pall Life Sciences, MI) to obtain platelet poor plasma. Fil-
tered plasma was aliquoted and immediately stored at -
80°C.
For serum processing, the tubes were left to clot for 30
minutes and then centrifuged at 2000 rpm for 10 min at
room temperature. Serum was collected leaving approxi-
mately 10% of serum above the buffy coat. To make it
directly comparable to the CTAD protocol, serum was also
filtered as mentioned above. Aliquots of 250 μL were
made and stored immediately at -80°C (time 0) or left onProteome Science 2009, 7:15 http://www.proteomesci.com/content/7/1/15
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the bench to be stored 30 min, 60 min, 120 min and 24 h
after centrifugation.
All samples used in the present study had been thawed
only once prior to this analysis. Our experience has shown
no change in clusterin levels after five freeze/thaw cycles
(data not shown).
Validation using ELISA analysis
For the measurement of clusterin we used a Human Clus-
terin ELISA kit (BioVendor, Czech Republic). Samples
were processed as recommended by the manufacturer and
read in a FLUOstar OPTIMA microplate reader (BMG
Labtech, Germany).
Results
Comparison of substrates and buffers
Important conditions for successful array preparation
include good spot morphology, spot reproducibility and
optimal protein attachment. Based on these criteria we
initiated the development of protocols to print serum and
plasma on reverse phase protein microarrays by testing
combinations of substrates and buffers. We tested three
different slide types, nitrocellulose, epoxy coated glass
slides and MaxiSorp™ black polymer plastic slides. Test
samples were prepared in two different buffers, a commer-
cially available non-denaturing buffer (PPB), and a dena-
turing buffer (Urea). Test samples included five two-fold
serial dilutions of human plasma. There were two subar-
rays per slide. The first subarray was composed of all test
samples prepared in the Urea buffer spotted in triplicate,
and the second subarray comprised samples prepared in
PPB also spotted in triplicate.
Slides were incubated with a primary antibody against
clusterin followed by Cy3 labeled secondary antibody.
Results from this experiment are shown in Table 1 and
Figure 1. Printing onto black plastic Maxisorp™ slides
resulted in low fluorescence intensity for all samples
printed with the PPB buffer. We observed some improve-
ment in protein attachment with Urea, but the sample did
not bind consistently on the Maxisorp™ slides resulting in
very poor spot reproducibility and no concordance
between the fluorescence intensities and the plasma dilu-
tions (Figure 1a). Although nitrocellulose performed
somewhat better with the Urea buffer, the conditions were
not optimal for the attachment of concentrated plasma
samples and higher background auto-fluorescence levels
were observed (Figure 1b). Optimal results for all the cri-
teria analysed were obtained when plasma samples were
prepared in the non-denaturing buffer (PPB) and printed
onto epoxy coated slides. Under these conditions, good
linearity of the fluorescence intensity corresponding to
the plasma serial dilutions was observed (Figure 1c). In
addition, low background and the lowest spot to spot var-
iability were also seen with this buffer and substrate com-
bination. Epoxy coated slides together with the buffer PPB
were used for all remaining experiments in this study.
Limit of detection and dynamic range of clusterin 
detection
To ensure that the detection of endogenous clusterin was
not due to non-specific binding from the secondary anti-
body, we printed two mini arrays each containing six
serial dilutions of commercially available human plasma
and six serial dilutions of mouse IgGs, each spotted in
triplicate. One array was probed with a mouse primary
antibody against human clusterin and a fluorescently
labeled anti-mouse IgG secondary antibody. The second
array was used as a negative control and was only incu-
bated with the anti-mouse IgG secondary antibody. Figure
2 shows that a fluorescent signal corresponding to the
detection of endogenous clusterin in plasma samples is
only seen when both primary and secondary antibodies
are used.
Since different antibodies show different affinity and spe-
cificity for the same target protein, we compared a poly-
clonal and a monoclonal antibody against clusterin and
assessed their limit of detection and dynamic range on
reverse phase protein microarrays. First, the specificity of
both antibodies was confirmed by western blot analysis
using the same human plasma samples spotted onto the
RPPM. The single band at ~37 kDa that is expected under
reducing conditions and that corresponds to the cleaved
alpha-chain of human sCLU was obtained for both the
polyclonal antibody (see Additional file 1) and the mon-
oclonal antibody (data not shown) confirming their spe-
cificity for clusterin. We prepared two slides where serial
plasma dilutions were spotted in quadruplicate in two
separate subarrays. Each array was probed with either the
monoclonal or polyclonal antibody against clusterin.
Table 1: Criteria Analysed for different substrates and buffers
Background Spot Morphology Spot Reproducibility
Substrate/Buffer PPB UREA PPB UREA PPB UREA
Nitrocellulose Moderate/High Moderate/High Squared Circle/donuts 9.9 11.2
MaxiSorp™ Low Low/Moderate Squared N/A 19.6 30.6
Epoxy Low Low/Moderate Squared N/A 6.7 15.7Proteome Science 2009, 7:15 http://www.proteomesci.com/content/7/1/15
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Quadruplicates of PPB were also spotted in each subarray
to serve as negative controls. The background-subtracted
mean fluorescent intensity of eight spots for each plasma
dilution was plotted (Figure 3a and 3b). With both anti-
bodies, the linearity of the signal for clusterin followed
the plasma dilution series until the signal tapered and was
not discernible from background level. With the polyclo-
nal antibody, less variability was seen between spots and
the fluorescent signal was more intense (10 fold differ-
ence) resulting in a dynamic range of 16 fold (plasma
diluted 4 to 64 fold) compared to 8 fold (plasma diluted
4 to 32 fold) for the monoclonal antibody. Whole plasma
and plasma diluted 2 fold were not spotted onto the array
since our preliminary results had showed a lot of variabil-
ity and signal saturation at these sample concentrations
(data not shown). The limit of detection (LOD) was deter-
mined with a standard method making use of this dilu-
tion curve generated with the plasma sample of known
concentration and identifying the amount of analyte that
produces a fluorescent signal at least two standard devia-
tions above the average fluorescence intensity of the back-
ground signal (eight control spots with PPB) [5,16]. Given
an initial clusterin concentration of 50 μg/mL in the
plasma samples used (measured with an ELISA kit) we
estimate that the LOD reached with the polyclonal anti-
body is approximately 780 ng/mL. If we take into consid-
eration the plasma dilution (plasma diluted 64 times)
and the minute amount of sample per spot (estimated as
Average fluorescence intensity of triplicate spots containing different plasma dilutions prepared in either PPB or Urea buffers  and spotted onto (a) MaxisSorp™, (b) nitrocellulose and (c) epoxy coatedslides Figure 1
Average fluorescence intensity of triplicate spots containing different plasma dilutions prepared in either PPB 
or Urea buffers and spotted onto (a) MaxisSorp™, (b) nitrocellulose and (c) epoxy coatedslides. Each buffer was 
also spotted alone as negative controls on each slide.Proteome Science 2009, 7:15 http://www.proteomesci.com/content/7/1/15
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0.7 nL according to the manufacturer of the spotting pins)
we can estimate that our RPPM can consistently detect at
least 546 femtograms of clusterin per spot. Because of its
superior results, the polyclonal anti-clusterin antibody
was used for all remaining experiments.
Minimum difference detected and reproducibility of RPPM
To identify the minimum difference in clusterin concen-
tration that can be detected on our reverse phase microar-
rays, we prepared a 1:4 dilution of plasma in PPB and
spiked it with increasing amounts of recombinant clus-
terin. Twenty concentrations of clusterin ranging from 0.5
ng to 250 μg per ml were spiked in a constant amount of
diluted plasma and each sample was spotted in quadru-
plicate. Three arrays were probed thus resulting in a total
of 12 data points for each concentration. Samples spiked
with the ten lowest clusterin concentrations (250-0.5 ng/
mL) yielded a low and relatively constant signal (data not
shown). The average fluorescent signal obtained from
these ten samples was attributed to endogenous clusterin
present in the plasma sample. The minimum difference
detected on our RPPMs was defined as the concentration
of spiked clusterin yielding a fluorescent signal at least
two standard deviations above the signal level for endog-
enous clusterin. We found that an increase of at least 8 μg/
ml of clusterin can be reliably detected on our platform
(Figure 3c). This is remarkable considering that the spik-
ing was done in plasma diluted only four fold, conserving
a fair degree of complexity compared to spiking done in
buffer only. The minimum difference detected is well
within the 50–250 μg/ml physiological range of plasma
clusterin in humans.
One of the major challenges in protein microarray print-
ing is to obtain consistent reproducibility between spots
and between arrays. We analysed spot-to-spot variability
and array-to-array variability with the results from this
same experiment. For intra-slide spot reproducibility, we
calculated the coefficient of variation (CV) of fluorescence
intensity for each set of quadruplicate spots and analysed
the distribution of %CVs in twenty sets of quadruplicates
per array. Overall %CV values were below 10% for all of
the samples, and the average %CV calculated for each
array was 5.5%, 4.1% and 3.9% for the three arrays.
Inter-array reproducibility was assessed by averaging the
fluorescence intensity of quadruplicates for each sample
and comparing it across arrays, for which %CVs were cal-
culated. We found that for replicate arrays the variability
ranged from 10–16% with mean %CV of 13% when the
raw average fluorescence data was used. In order to
remove any systematic variation we applied a scaled to
median normalization method to our data (see methods).
Following normalization, the coefficient of variation
between arrays was significantly reduced to a range of 0.1
– 8.4% with a mean %CV of 2.2%.
Validation of RPPM results with ELISA
We validated the clusterin measurements performed on
the reverse phase protein microarrays by comparing with
results obtained from an ELISA assay performed on the
same samples. Plasma diluted four fold was spiked with
increasing concentrations of recombinant clusterin rang-
ing from 0.9 μg/mL to 500 μg/mL. Each sample was meas-
ured in duplicate using a commercially available ELISA kit
Scanned image of fragments of RPPMs showing spotted triplicates of plasma and mouse IgGs probed with (+) or without (-)  primary anti-clusterin antibody, and with secondary fluorescently labeled anti-IgG antibody Figure 2
Scanned image of fragments of RPPMs showing spotted triplicates of plasma and mouse IgGs probed with (+) 
or without (-) primary anti-clusterin antibody, and with secondary fluorescently labeled anti-IgG antibody. 
Pseudo-color scale, dark blue to white corresponds to increasing fluorescence.
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(BioVendor Inc) and in quadruplicate on a reverse phase
microarray. Three subarrays were probed and the average
fluorescence of 12 data points for each sample was plotted
against its respective ELISA value. Figure 3d shows that
results from both platforms correlate very well with a cor-
relation coefficient r of 0.984. These results demonstrate
that clusterin spiked in a complex plasma sample can be
reliably measured using reverse phase protein microar-
rays.
Clinical samples
In order to evaluate the clinical applicability of our plat-
form, we used RPPMs to measure the levels of clusterin in
149 clinical blood samples. These clinical samples were
obtained from eleven healthy individuals who partici-
pated in a pilot study to determine the effects of different
blood processing protocols on levels of mid and low-
abundant plasma biomarkers. As pre-analytical variability
is one major factor of concern in proteomics studies, we
used our platform to assess whether or not clusterin levels
varied when using different blood processing protocols.
For each subject, whole blood was collected in three
blood collection tubes in the following order: citrate-the-
ophylline-adenosine-dipyridamole (CTAD) tube, serum
tube, and CTAD tube. We decided to use CTAD plasma
collection tubes as they stabilize platelets and prevent
Evaluation parameters of RPPMs Figure 3
Evaluation parameters of RPPMs. (a) Detection of clusterin in plasma samples using monoclonal and (b) polyclonal pri-
mary anti-clusterin antibodies. The log10 average signal intensity for clusterin was plotted against plasma dilution 1/4 to 1/512. 
(c) Minimum difference in clusterin concentration detected on RPPMs. Twenty different concentrations of recombinant clus-
terin were spiked in plasma and the average fluorescence intensity of three slides median normalized was plotted against the 
ten highest clusterin concentrations. The average fluorescence level (▲) with the value of 2 standard deviations (---) for the ten 
lowest endogenous clusterin concentrations are used as background clusterin level in this experiment. Arrow points to the 
concentration of spiked clusterin that yielded a signal at least 2SD above background plasma clusterin. (d) Correlation of clus-
terin levels measured with ELISA and RPPM (r = 0.989). Clusterin was measured in plasma samples spiked with increasing con-
centrations (0.9–500 μg/ml) of recombinant clusterin.
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platelet degranulation. Clusterin is present in significant
quantities in platelets, and thus the use of different types
of collection tubes could yield different clusterin concen-
trations from the same patient. Each blood sample was
processed with a specific protocol testing the effect of dif-
ferent delays of blood processing after blood collection
ranging from time zero to 24 hours. Plasma and serum
samples were diluted 1:4 in buffer and spotted in quadru-
plicates, four replicate arrays were analysed resulting in
596 sets of quadruplicates or 2384 data points in total
(Figure 4). In order to include only good quality array
data in the validation analysis we filtered for spot quality
(see methods). Overall spot reproducibility was very good
with 84% of quadruplicate sets with %CV below 10%. For
18 sets the variability did not meet the criteria (%CV >
20%) and one spot was removed from the analysis in 15
of these quadruplicate sets. In total, 7 whole sets of quad-
ruplicates were removed from the analysis due to low spot
intensity or bad spot quality. All the remaining data for
the four arrays was median normalized as previously
described (methods), and for each sample, the median
intensity of all 4 replicate arrays was considered to be the
clusterin signal. The distribution of clusterin relative
expression across the different samples analysed is shown
in Figure 5a. We observed that the levels of clusterin
detected on the protein microarray were significantly
higher in serum samples when compared to CTAD (p <
0.001). On the other hand, delaying sample processing
for up to 24 hours did not significantly affect clusterin
serum and plasma levels (Fig 5b). Similar results were
obtained after validation using an ELISA assay (Fig 5c).
Since a much larger number of samples had been spotted
compared to our previous tests, we again performed inter-
array variability analysis and obtained very good repro-
ducibility with an average %CV of 11%.
In order to directly compare the fluorescence intensities
from reverse phase protein microarrays to the measured
clusterin levels obtained by ELISA, we scaled the array
data as reported by Janzi et al [9] and as described in the
methods section. Briefly, for those samples with corre-
sponding ELISA values (140 in total since no ELISA values
were obtained for samples from one of the volunteers) a
scaling factor was calculated and applied to each data
point. The correlation between the RPPM data and the
ELISA results for all samples is shown in figure 5d. Almost
the totality of the samples analysed (98.6%) had a log2
ratio between 1 and -1 indicating a very good overall cor-
relation across the range of clusterin concentrations.
Direct comparison of median normalized RPPM data to
ELISA values was also performed. For each set of samples
collected from the same subject a correlation to the corre-
sponding ELISA values was performed. Therefore we
obtained ten correlation coefficients with r values ranging
from 0.51 to 0.93 and with median of 0.71.
Discussion
The major bottleneck in translating newly discovered
biomarkers to the clinic is the validation of these discov-
eries in controlled clinical samples [17]. We and others are
developing a novel high-throughput platform to meet the
challenge of biomarker validation in human blood sam-
ples, using reverse-phase protein microarrays (RPPMs).
Although RPPMs for cell and tissue lysates are used exten-
sively and protocols are available [18-20] there are few
reports on the use of RPPMs for serum and plasma sam-
ples and no specific protocol has been defined
[8,9,21,22]. In the present study we developed an optimal
spotting protocol, including the choice of a printing
buffer and surface chemistry, for the printing of plasma
and serum in the reverse array format, and we assessed the
applicability of RPPMs for the measurement of a mid-
abundant plasma biomarker, clusterin.
The type of substrate and printing buffer used for microar-
ray fabrication, in addition to sample properties such as
viscosity and surface tension, have a major influence on
array quality parameters including spot morphology,
background and protein affinity binding [23]. In the prep-
aration of reverse phase protein microarrays for cell and
tissue lysates, nitrocellulose remains the most commonly
Scanned image of slide containing 149 clinical samples spotted in quadruplicate and probed for clusterin Figure 4
Scanned image of slide containing 149 clinical samples spotted in quadruplicate and probed for clusterin.Proteome Science 2009, 7:15 http://www.proteomesci.com/content/7/1/15
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used substrate [24-27]. This surface allows proteins to
bind non-covalently (hydrophobic interaction) to the sur-
face and also provides high binding capacity allowing the
detection of very low abundant analytes when using cata-
lysed signal amplification detection methods [5,18].
However, one of the drawbacks of nitrocellulose is its high
intrinsic fluorescence that results in high background lev-
els, thereby limiting the sensitivity of the assay when flu-
orescently labelled antibodies are used for detection [28].
In our hands, plasma binding to nitrocellulose was lim-
ited, and, together with the higher background levels, it
resulted in a lower dynamic range for the measurement of
an endogenous protein, clusterin, when compared to
epoxy coated slides. Although nitrocellulose performs
very well for printing denatured cell and tissue lysates, we
did not find it yield satisfactory results for serum and
plasma RPPMs when using a fluorimetric detection
method compared to epoxy, therefore no further develop-
ment to deal with the autofluorescence issue of nitrocellu-
lose was pursued. We also found that MaxiSorp™ black
polymer slides, which perform well in forward-phase anti-
body microarrays [29-31], showed the poorest binding
results and spot morphology with both of the buffers
tested on our reverse phase arrays, suggesting that plasma
samples may be incompatible with the hydrophilic chem-
istry of the substrate. Our best results were obtained when
epoxy coated slides and non-denaturing PPB buffer were
used in combination. Epoxy surfaces offer several advan-
tages including covalent immobilization, a more diffuse
distribution of the proteins on the slide, and low non-spe-
cific background [32,33]. The more diffuse binding pat-
tern of proteins on the slide may increase the chance of
Measurement of clinical samples using RPPMs andELISA Figure 5
Measurement of clinical samples using RPPMs andELISA. (a) The log10 median clusterin intensity of all clinical samples 
analysed was plotted. (b) Clusterin levels in serum and CTAD plasma samples taken from the same individual and processed at 
different time points (0 min to 24 hrs) were measured with ELISA and (c) RPPM. (d) Correlation of RPPM data and ELISA val-
ues obtained for all clinical samples. The scaled data of all 16 data points per sample was averaged and then divided by its 
respective clusterin concentration measured by ELISA to obtain a ratio. For each sample, the log2 ratio was plotted against its 
respective clusterin concentration measured by ELISA.
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the antibody binding to its epitope since blood proteins
are spotted in their native conformation with the PPB
buffer.
In the present study we provide proof of principle for the
detection of human endogenous clusterin, a mid-abun-
dant blood protein, in plasma and serum using RPPMs
and fluorescently labelled secondary antibodies. The sen-
sitivity and specificity of any antibody based assay is
largely dependent on antibody performance. We found
that the polyclonal antibody targeted against clusterin
showed a dynamic range 2-fold greater than that of the
monoclonal antibody. Interestingly, spot variability was
also reduced when slides were probed with the polyclonal
antibody. It is worthwhile noting that both antibodies
had demonstrated the pre-requisite specificity, recogniz-
ing a single band at the expected molecular weight in
western blot analysis of the same complex sample used for
the RPPM experiment. As with any use of reverse phase
protein microarrays, careful screening of the specificity of
antibodies is necessary; in addition, we suggest screening
for dynamic range before selecting the optimal antibody
to be used on the RPPM platform.
The sensitivity of any biomarker validation technology
needs to be sufficiently high to enable the detection of low
abundant protein biomarkers. Here we report a limit of
detection (LOD) in the ng/mL range (780 ng/ml), which
is approximately 100 fold less than the plasma levels of
the endogenous mid abundant serum/plasma protein
clusterin, using RPPMs in the absence of signal amplifica-
tion detection methods. Although the LOD reached was
essentially identical to that of the ELISA assay used in our
validation studies (750 ng/mL), the sensitivity of our
RPPM platform was significantly higher if we consider
that we could detect this low amount of analyte from only
0.7 nL of biological sample. Our results suggest that the
RPPM platform can be used for the high throughput and
reproducible detection of mid abundant blood protein
biomarkers. It is possible that the limit of detection can be
lowered using different amplification techniques such as
TSA amplification or the use of nanoparticles such as
quantum dots. However, amplification methods were
clearly not required for the accurate detection of clusterin
on our platform.
We focused the development of our platform for the
detection of clusterin. Blood clusterin levels have been
shown to change in different disease states including
numerous cancers [34] and systemic lupus erythematosus
[35] as well as in diabetic type II patients and in patients
with developing coronary heart disease, or myocardial inf-
arction [36]. Preliminary evidence also suggests that
measurement of clusterin in serum and plasma may be
useful for the early detection of colorectal cancer [37] and
for monitoring pVHL-defective renal carcinomas [38].
Moreover, changes in clusterin levels are being studied as
surrogate biomarkers for treatment efficacy in clinical tri-
als of anti-clusterin therapy in breast, lung and prostate
cancer [39,40]. In our platform, the minimal difference of
8 μg of clusterin that can be detected between samples is
clearly in the range of clinically relevant changes in
plasma clusterin. Moreover, the good correlation with
ELISA values and the low spot to spot variability and array
to array variability observed when large numbers of clini-
cal samples are screened further demonstrates that RPPMs
for the detection of clusterin hold potential for clinical
applicability. We feel that these results are all the more
remarkable as they were obtained using only samples
from healthy volunteers, in which clusterin levels showed
very limited variation. In fact, our RPPM platform was
useful to assess whether clusterin levels changed when
using different blood processing protocols. We could
observe a relationship between the levels of clusterin and
the type of blood collection tube used. We used CTAD
tubes which contain citrate-theophylline-adenosine-dipy-
ridamole and inhibit platelet activation [41]. As clusterin
is highly expressed in platelets [42], inhibiting platelet
activation and thus the release of clusterin from platelets,
is likely to explain the lower clusterin levels observed in
CTAD plasma compared to serum. Our results are similar
to those from a previous study which had recommended
the use of citrate plasma for the measurement of clusterin
[43], but this is, to our knowledge, the first report measur-
ing plasma clusterin levels in CTAD tubes. Furthermore,
the comparison of both CTAD specimens from the same
individual showed that the levels of clusterin do not
change from the first and third blood draw, thus suggest-
ing that, when measuring clusterin, it may not be neces-
sary to discard the first tube as sometimes recommended
in blood collection guidelines. The results from our RPPM
analysis and further validation with ELISA assays further
confirm that blood collection protocols require careful
standardization and that the differences in serum and
plasma levels need to be taken into consideration in the
course of clinical studies measuring clusterin levels.
Ideally, a clinically useful biomarker should be detected in
serum or plasma. Prior to the clinical adoption of biomar-
ker-based tests, putative biomarkers need to be rigorously
validated in thousands of clinical samples. With RPPMs it
is possible to spot hundreds if not thousands of serum
and plasma samples on a single slide and analyze a
biomarker of interest in one single experiment. Although
the platform is presently limited by antibody availability
and specificity, this is likely to change in the near future
thanks to global initiatives such as the Human Antibody
Initiative from HUPO and the Swedish Human Proteome
Resource (HPR) program, which focus on the develop-Proteome Science 2009, 7:15 http://www.proteomesci.com/content/7/1/15
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ment of high quality antibodies against all human pro-
teins [44].
One alternative method for biomarker validation is mul-
tiple reaction monitoring mass spectrometry (MRM-MS)
[45]. This method is very attractive since it does not
require antibodies for the detection and measurement of
biomarkers; however, it has not yet reached the required
sensitivity for low abundant proteins in complex samples
such as serum and plasma. Moreover, although many
biomarkers can be simultaneously monitored in a sample,
it has a limited throughput since only one sample can be
analyzed at a time. From a practical perspective, if an anti-
body is available for a biomarker of interest, antibody
based methods such as RPPMs, are more easily adopted as
validation tools than mass spectrometry based methods
[46].
Conclusion
In the present study we demonstrate the clinical applica-
bility of RPPMs for the measurement of mid-abundant
plasma proteins such as clusterin. Further technical
improvements to the platform will have to be imple-
mented to lower the limit of detection of plasma biomar-
kers to that of most clinically relevant markers, i.e. in the
low nanogram/mL and picogram/mL range. With greater
sensitivity, reverse phase protein microarrays offer the
potential to speed up the validation process awaiting hun-
dreds of putative disease biomarkers and their translation
to the clinical setting.
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